BridgeBio rises as sales of heart disease drug drive quarterly revenue beat

Shares of drugmaker BridgeBio Pharma BBIO.O rise 2.5% to $37.33

Co late on Tuesday posted Q1 sales of $116.6 million, exceeding analysts' average estimate of $61.9 million, according to data compiled by LSEG

Co's heart disease drug Attruby, which competes with Alnylam's ALNY.O Amvuttra and Pfizer's PFE.N Vyndamax, brought in sales of $36.7 million for the quarter

Attruby treats ATTR-CM, a condition where faulty transthyretin proteins accumulate in the heart, potentially causing organ to fail

"We think ATTR-CM is a large market... a widening prescriber base should support meaningful continued growth of Attruby patients," say UBS analysts

Inluding session's move, BBIO stock up 36.3% YTD